Rapid Japan review sets stage for Xeljanz's second approval worldwide
This article was originally published in Scrip
Executive Summary
In a move that clears the way to only its second approval worldwide, Japan has given a positive opinion to Pfizer's novel rheumatoid arthritis (RA) drug Xeljanz (tofacitinib citrate).